Clinical Scorecard: Assessment of the Safety and Effectiveness of Bupleurum-Infused Formulas in Conjunction with Chemotherapy for Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis

At a Glance

Key Highlights

• Bupleurum formulas combined with chemotherapy improved objective response rate (ORR) and disease control rate (DCR).
• Quality of life (QOL) was significantly enhanced with the combined treatment.
• The regimen reduced the incidence of grade III-IV gastrointestinal adverse events.
• Interventions lasting ≥12 weeks showed greater improvements in ORR.
• The study followed PRISMA guidelines and was registered in the PROSPERO database.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of TNBC should be based on histopathological or cytological criteria.

Management

• Consider Bupleurum-containing TCM formulas as an adjunct to chemotherapy for TNBC.

Monitoring & Follow-up

• Monitor clinical outcomes including ORR, DCR, and QOL in patients receiving combined treatment.

Risks

• Be aware of potential gastrointestinal adverse events associated with chemotherapy.

Patient & Prescribing Data

Patients with Triple-Negative Breast Cancer undergoing chemotherapy.

Bupleurum-containing formulas may enhance treatment efficacy and reduce toxicity.

Clinical Best Practices

• Utilize Bupleurum formulas in conjunction with chemotherapy to improve patient outcomes.
• Conduct further high-quality studies to validate findings.

Related Resources & Content

• Systematic Review Registration